Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Protagonist Therapeutics, Inc. is a clinical-stage biotechnology company focused on the discovery and development of peptide-based therapeutics designed to modulate clinically validated biological targets. The company operates primarily within the biopharmaceutical and life sciences industries, with an emphasis on inflammatory, immunological, and hematologic diseases. Its core strategy centers on engineering peptides that combine the specificity of biologics with the convenience of oral or injectable delivery.
The company’s primary value drivers are its proprietary peptide technology platform and its clinical-stage drug candidates, most notably rusfertide (PTG‑300) for hematologic disorders and JNJ‑2113 (formerly PN‑235) for immune-mediated inflammatory diseases. Protagonist serves pharmaceutical partners and, ultimately, patients with chronic diseases that require long-term therapy. Founded in 2006, the company evolved from a discovery-focused peptide engineering firm into a late-stage clinical developer through internal R&D and strategic collaborations with large pharmaceutical companies.
Business Operations
Protagonist Therapeutics generates value through internal drug development and strategic partnerships, with operations centered on research, clinical development, and regulatory advancement rather than commercial sales. Its operating activities are primarily organized around hematology programs and immunology and inflammation programs, with expenditures focused on clinical trials, manufacturing of clinical materials, and regulatory compliance.
The company does not currently market approved products and therefore does not generate product sales revenue. Instead, revenue has historically consisted of collaboration payments, milestone payments, and research funding from partners. Protagonist controls a proprietary peptide discovery and optimization platform and maintains full or shared rights to its clinical assets, while leveraging partnerships for late-stage development and potential commercialization.
Strategic Position & Investments
Protagonist’s strategic direction emphasizes advancing late-stage clinical assets while selectively partnering programs to offset development risk and capital requirements. A central element of this strategy is its collaboration with Janssen Biotech, Inc., a subsidiary of Johnson & Johnson, for JNJ‑2113, an oral peptide targeting the interleukin‑23 receptor. This partnership includes significant upfront consideration and the potential for development, regulatory, and commercial milestones.
Another key strategic asset is rusfertide (PTG‑300), a hepcidin mimetic being developed for polycythemia vera and other hematologic conditions. Rusfertide remains wholly owned by Protagonist as of the latest publicly available disclosures, though the company has indicated openness to strategic alternatives. The company continues to invest in expanding its peptide platform to address additional validated targets. Some partnership timelines and future commercialization structures remain data inconclusive based on available public sources.
Geographic Footprint
Protagonist Therapeutics is headquartered in the United States, with its principal executive offices in California. Its operations are primarily U.S.-based, including research, clinical management, and corporate functions. The company conducts clinical trials across North America and Europe, reflecting the geographic distribution typical of mid- to late-stage biotechnology development programs.
Through its strategic partnerships, particularly with multinational pharmaceutical companies, Protagonist maintains indirect operational and developmental influence across global markets, including Europe and Asia-Pacific, where partnered clinical development and future commercialization activities may occur.
Leadership & Governance
Protagonist Therapeutics was founded by Dinesh V. Patel, who continues to play a central role in shaping the company’s scientific and strategic direction. The leadership team combines expertise in peptide chemistry, clinical development, and biopharmaceutical finance, with a governance structure typical of a publicly traded biotechnology company.
- Dinesh V. Patel – President, Chief Executive Officer, and Director
- Sameer Doshi – Chief Financial Officer
- Saurabh Saha – Chief Medical Officer
- Jonathan Z. Chen – Chief Scientific Officer
The leadership philosophy emphasizes disciplined capital allocation, scientifically validated targets, and partnerships with established pharmaceutical companies to maximize long-term shareholder and patient value.